Coord Core - Atkinson

坐标核心 - 阿特金森

基本信息

  • 批准号:
    10254841
  • 负责人:
  • 金额:
    $ 135.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-08 至 2022-06-30
  • 项目状态:
    已结题

项目摘要

Extensive clinical research studies are urgently needed to inform patient management strategies and develop pharmaceutical countermeasures to combat the 2019 novel coronavirus disease (COVID-19). Currently, COVID-19 infections and hospitalizations are surging across the state of Florida; hence, we propose to establish the University of Florida (UF) as a subject-enrollment and sample collection center for the Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study at three Florida health science centers. In this nationwide prospective observational study, peripheral blood and nasal swabs will be frequently collected from consented hospitalized patients with confirmed COVID-19, with endotracheal aspirates also collected if the patient requires intubation. After participants are discharged, blood and nasal swabs will be collected during outpatient visits held at three-month intervals over the course of one year, allowing for longitudinal analysis of the virus’s effects on the immune system both during active infection and following recovery. Through the OneFlorida Clinical Research Consortium (CRC), we already have established infrastructure including trained staff to support participant consenting/enrollment and sample collection, as well as on site laboratory facilities for sample processing. In Aim 1, we propose to integrate three OneFlorida CRC collection sites (Tampa General Hospital/University of South Florida, UF Health Jacksonville Medical Center, and UF Health Shands Hospital in Gainesville) into the IMPACC study. These sites have sufficient COVID-19 caseload to support enrollment of 100 participants over the course of the four-month recruitment period. In Aim 2, samples will be processed immediately upon collection and shipped to six core laboratories for precision medicine genotyping, viral sequencing, proteomics/metabolomics, antibody measurement and isotyping, as well as immunophenotyping by CyTOF. From these collective data, IMPACC seeks to link viral burden with immune signatures as biomarkers of acute disease severity, mortality, the development of durable immunity, and long-term outcomes in survivors. Moreover, extensive immunophenotyping data has the potential to uncover new therapeutic targets to mitigate the disease severity. Initially, COVID-19 mortality was attributed to a cytokine storm and enhanced thrombosis, supporting treatment with immunosuppressive drugs in patients with severe disease. However, in an effort to support the power of immmuophenotyping to provide key information, we provide preliminary data suggesting that immunosuppression is a primary concordant feature of the disease, potentially arguing against the routine use of immunosuppressant medications. These data also demonstrate our ability to perform single cell RNA sequencing (scRNAseq), scATACseq, spectral flow cytometry, and ELISpot to evaluate gene expression, chromatin accessibility, protein expression, and immune cell function, respectively. With the consortium’s approval to use residual IMPACC samples, these site-specific assays could be funded through outside mechanisms and the data shared across the IMPACC consortium.
迫切需要广泛的临床研究,以告知患者管理策略和开发 对抗2019年新型冠状病毒疾病(COVID-19)的药物对策。目前, COVID-19感染和住院人数在佛罗里达州激增;因此,我们建议 建立佛罗里达大学(UF)作为受试者招募和样本收集中心, 佛罗里达三所卫生科学中心的COVID-19队列研究(IMPACC)中的免疫表型评估 中心.在这项全国性的前瞻性观察性研究中,外周血和鼻拭子将经常 收集自确诊COVID-19的知情同意住院患者,气管内抽吸物也 如果患者需要插管,则收集。受试者出院后,将采集血液和鼻拭子 在一年内每隔三个月举行的门诊访视期间收集, 在活动性感染期间和感染后病毒对免疫系统影响的纵向分析 复苏通过OneFlorida临床研究联盟(CRC),我们已经建立了 基础设施,包括经过培训的工作人员,以支持参与者知情同意/入组和样本采集,以及 作为用于样品处理的现场实验室设施。在目标1中,我们建议整合三个OneFlorida CRC 收集地点(坦帕综合医院/南佛罗里达大学,UF健康杰克逊维尔医疗中心, 和盖恩斯维尔的UF Health Shands医院)纳入IMPACC研究。这些网站有足够的COVID-19 在为期四个月的征聘期间,将有100名参与者参加。在Aim中 2,样本将在采集后立即处理,并运送到六个核心实验室进行精密度检测 医学基因分型、病毒测序、蛋白质组学/代谢组学、抗体测量和同种型, 以及通过CyTOF进行免疫表型分析。根据这些收集的数据,IMPACC试图将病毒负荷与 作为急性疾病严重程度、死亡率、持久免疫力发展的生物标志物的免疫特征, 以及幸存者的长期结果。此外,广泛的免疫表型数据有可能 发现新的治疗靶点以减轻疾病的严重程度。最初,COVID-19死亡率归因于 细胞因子风暴和增强的血栓形成,支持患者使用免疫抑制药物治疗 患有严重疾病。然而,为了支持免疫表型分析的力量, 信息,我们提供的初步数据表明,免疫抑制是一个主要的一致性特征, 这种疾病,可能反对常规使用免疫抑制剂药物。这些数据还 展示我们进行单细胞RNA测序(scRNAseq)、scATACseq、光谱流 流式细胞术和ELISpot来评估基因表达、染色质可及性、蛋白质表达和免疫原性。 细胞功能。在财团批准使用残余IMPACC样品后, 可以通过外部机制资助分析,并在IMPACC联盟中共享数据。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK A. ATKINSON其他文献

MARK A. ATKINSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK A. ATKINSON', 18)}}的其他基金

Human Pancreas Analysis Program-T2D
人类胰腺分析程序-T2D
  • 批准号:
    10907128
  • 财政年份:
    2023
  • 资助金额:
    $ 135.15万
  • 项目类别:
Biorepository and Coordinating Center for Studies on Cardiovascular Complications of Human Type 1 Diabetes
人类1型糖尿病心血管并发症研究生物储存库和协调中心
  • 批准号:
    10879240
  • 财政年份:
    2022
  • 资助金额:
    $ 135.15万
  • 项目类别:
Biorepository and Coordinating Center for Studies on Cardiovascular Complications of Human Type 1 Diabetes
人类1型糖尿病心血管并发症研究生物储存库和协调中心
  • 批准号:
    10672443
  • 财政年份:
    2022
  • 资助金额:
    $ 135.15万
  • 项目类别:
Biorepository and Coordinating Center for Studies on Cardiovascular Complications of Human Type 1 Diabetes
人类1型糖尿病心血管并发症研究生物储存库和协调中心
  • 批准号:
    10512888
  • 财政年份:
    2022
  • 资助金额:
    $ 135.15万
  • 项目类别:
Co-registration of Cell Organization, Phenotype and Function in the Human Pancreas During Type 1 Diabetes
1 型糖尿病期间人类胰腺细胞组织、表型和功能的共同注册
  • 批准号:
    10343979
  • 财政年份:
    2021
  • 资助金额:
    $ 135.15万
  • 项目类别:
Co-registration of Cell Organization, Phenotype and Function in the Human Pancreas During Type 1 Diabetes
1 型糖尿病期间人类胰腺细胞组织、表型和功能的共同注册
  • 批准号:
    10673726
  • 财政年份:
    2021
  • 资助金额:
    $ 135.15万
  • 项目类别:
Co-registration of Cell Organization, Phenotype and Function in the Human Pancreas During Type 1 Diabetes
1 型糖尿病期间人类胰腺细胞组织、表型和功能的共同注册
  • 批准号:
    10490416
  • 财政年份:
    2021
  • 资助金额:
    $ 135.15万
  • 项目类别:
Regional and lobular heterogeneity of human pancreas morphology and function in type 1 diabetes pathogenesis
1型糖尿病发病机制中人胰腺形态和功能的区域和小叶异质性
  • 批准号:
    10400943
  • 财政年份:
    2020
  • 资助金额:
    $ 135.15万
  • 项目类别:
Regional and lobular heterogeneity of human pancreas morphology and function in type 1 diabetes pathogenesis
1型糖尿病发病机制中人胰腺形态和功能的区域和小叶异质性
  • 批准号:
    10617206
  • 财政年份:
    2020
  • 资助金额:
    $ 135.15万
  • 项目类别:
Regional and lobular heterogeneity of human pancreas morphology and function in type 1 diabetes pathogenesis
1型糖尿病发病机制中人胰腺形态和功能的区域和小叶异质性
  • 批准号:
    10223289
  • 财政年份:
    2020
  • 资助金额:
    $ 135.15万
  • 项目类别:

相似海外基金

REU Site: Design, Create, and Innovate 3-Dimensional User Interfaces to Improve Human Sensory and Motor Performance in Virtual Environments (HUMANS MOVE)
REU 网站:设计、创建和创新 3 维用户界面,以提高虚拟环境中的人类感官和运动表现 (HUMANS MOVE)
  • 批准号:
    2349771
  • 财政年份:
    2024
  • 资助金额:
    $ 135.15万
  • 项目类别:
    Standard Grant
CAREER: Atomic-level understanding of stability and transition kinetics of 3-dimensional interfaces under irradiation
职业:对辐照下 3 维界面的稳定性和转变动力学的原子水平理解
  • 批准号:
    2340085
  • 财政年份:
    2024
  • 资助金额:
    $ 135.15万
  • 项目类别:
    Continuing Grant
Artificial fabrication of 3-dimensional noncollinear magnetic order and magnetization manipulation by spin torque
三维非共线磁序的人工制造和自旋转矩磁化操纵
  • 批准号:
    23H00232
  • 财政年份:
    2023
  • 资助金额:
    $ 135.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Understanding of 3-dimensional seismic behavior of RC frame high-speed railway/highway viaducts using FE analysis
使用有限元分析了解 RC 框架高速铁路/公路高架桥的 3 维抗震性能
  • 批准号:
    23H01489
  • 财政年份:
    2023
  • 资助金额:
    $ 135.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Modernization of 3-dimensional printing capabilities at the Aquatic Germplasm and Genetic Resource Center
水产种质和遗传资源中心 3 维打印能力的现代化
  • 批准号:
    10736961
  • 财政年份:
    2023
  • 资助金额:
    $ 135.15万
  • 项目类别:
The 3-dimensional nest of the honey bee: organization, development, and impact on colony function
蜜蜂的 3 维巢穴:组织、发育及其对蜂群功能的影响
  • 批准号:
    2216835
  • 财政年份:
    2023
  • 资助金额:
    $ 135.15万
  • 项目类别:
    Standard Grant
Research on high-density 3-dimensional polymer optical waveguide device for photonics-electronics convergence
光电子融合高密度三维聚合物光波导器件研究
  • 批准号:
    23H01882
  • 财政年份:
    2023
  • 资助金额:
    $ 135.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Scaff-Net: 3 Dimensional multiphoton polymerisation printed scaffolds for medium throughput recording from stem cell derived human cortical networks.
Scaff-Net:3 维多光子聚合打印支架,用于从干细胞衍生的人类皮质网络进行中等通量记录。
  • 批准号:
    EP/X018385/1
  • 财政年份:
    2023
  • 资助金额:
    $ 135.15万
  • 项目类别:
    Research Grant
3-dimensional prompt gamma imaging for online proton beam dose verification
用于在线质子束剂量验证的 3 维瞬发伽马成像
  • 批准号:
    10635210
  • 财政年份:
    2023
  • 资助金额:
    $ 135.15万
  • 项目类别:
Equipment: MRI: Track 1 Acquisition of a 3-Dimensional Nanolithography Instrument
设备:MRI:轨道 1 获取 3 维纳米光刻仪器
  • 批准号:
    2320636
  • 财政年份:
    2023
  • 资助金额:
    $ 135.15万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了